SCHEMBL439390

SCHEMBL439390

CCS(=O)(=O)ON(CCO)CCO

nearest known ligand 0.32

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25294584 0.85 CA1 (0.30)
SCHEMBL25255398 0.81 ALDH1A1 (0.32) MAPTSMN1; SMN2
SCHEMBL28582202 0.78 FAAH (0.39)
SCHEMBL27930100 0.73 SMN1; SMN2 (0.35) SMN1; SMN2
SCHEMBL29206586 0.68
SCHEMBL361494 0.66
SCHEMBL25297672 0.65 FAAH (0.33) MAPTSMN1; SMN2
SCHEMBL2321357 0.65
SCHEMBL25298936 0.64 NPC1 (0.35) MAPTSMN1; SMN2
SCHEMBL14336083 0.64 MAPT (0.38) MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12171785-B2 Pluripotent cells derived from bone marrow and methods for isolation REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2024-12-24 US disclosed
US-20230302058-A1 TREATMENT OF LYMPHEDEMA AND RELATED CONDITIONS USING PLACENTAL ADHERENT CELLS CELULARITY INC. (US) 2023-09-28 US disclosed
WO-2023149262-A1 METHOD FOR FORMING MULTILAYER COATING FILM 関西ペイント株式会社 2023-08-10 WO disclosed
WO-2023149261-A1 METHOD FOR FORMING MULTILAYER COATING FILM 関西ペイント株式会社 2023-08-10 WO disclosed
US-11197889-B2 Immunomodulatory properties of multipotent adult progenitor cells and uses thereof ABT HOLDING COMPANY (US) 2021-12-14 US disclosed
US-20210346429-A1 IMMUNOMODULATORY PROPERTIES OF MULTIPOTENT ADULT PROGENITOR CELLS AND USES THEREOF ABT HOLDING COMPANY (US) 2021-11-11 US disclosed
US-20210230537-A1 ANGIOGENESIS USING STIMULATED PLACENTAL STEM CELLS CELULARITY INC. (US) 2021-07-29 US disclosed
US-10870834-B2 Isolated populations of adult renal cells and methods of isolating and using same TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. (IL) 2020-12-22 US disclosed
US-20190314424-A1 TREATMENT OF LYMPHEDEMA AND RELATED CONDITIONS USING PLACENTAL ADHERENT CELLS Celularity, Inc. (US) 2019-10-17 US disclosed
EP-3548051-A1 TREATMENT OF LYMPHEDEMA AND RELATED CONDITIONS USING PLACENTAL ADHERENT CELLS Celularity, Inc. (US) 2019-10-09 EP disclosed
US-20060008450-A1 Use of multipotent adult stem cells in treatment of myocardial infarction and congestive heart failure REGENTS OF THE UNIVERSITY OF MINNESOTA 2006-01-12 US disclosed
WO-2005112959-A2 USE OF UMBILICAL CORD BLOOD STEM CELLS TO TREAT ISCHEMIC EVENT REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2005-12-01 WO disclosed
WO-2005113748-A2 MAPC GENERATION OF LUNG TISSUE REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2005-12-01 WO disclosed
US-20050181502-A1 Multipotent adult stem cells and methods for isolation ATHERSYS, INC. (US) 2005-08-18 US disclosed
WO-2005021738-A1 KIDNEY DERIVED STEM CELLS AND METHODS FOR THEIR ISOLATION, DIFFERENTIATION AND USE REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2005-03-10 WO disclosed
EP-1226233-A2 MULTIPOTENT ADULT STEM CELLS AND METHODS FOR ISOLATION MCL LLC (US) 2002-07-31 EP disclosed
WO-2001011011-A9 MULTIPOTENT ADULT STEM CELLS AND METHODS FOR ISOLATION MCL LLC (US) 2002-07-25 WO disclosed
US-6274748-B1 MIXING FATTY ACID WITH AN AMINO OXY ALKANE; HEATING; DEHYDRATION ZENITH COSMETIC TECHNOLOGIES LLC 2001-08-14 US disclosed
WO-2001045503-A2 CRYOPRESERVATION COMPOSITIONS AND METHODS FOR PERIPHERAL BLOOD LYMPHOCYTES REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2001-06-28 WO disclosed
WO-2001011011-A2 MULTIPOTENT ADULT STEM CELLS AND METHODS FOR ISOLATION MCL LLC (US) 2001-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210230537-A1 ANGIOGENESIS USING STIMULATED PLACENTAL STEM CELLS PGF, FLT4, FLT1 MAPT 4870/4885SMN1; SMN2 4808/4885
US-20190314424-A1 TREATMENT OF LYMPHEDEMA AND RELATED CONDITIONS USING PLACENTAL ADHERENT CELLS PGF, CDH1, CXCL12 MAPT 3917/4885SMN1; SMN2 3550/4885
US-20230302058-A1 TREATMENT OF LYMPHEDEMA AND RELATED CONDITIONS USING PLACENTAL ADHERENT CELLS PGF, CDH1, CXCL12 MAPT 3917/4885SMN1; SMN2 3550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.